B
Bivision
A biomedical enterprise focusing on the research and development of targeted radiopharmaceuticals (TRT)
About Bivision
Bivision Pharmaceuticals, co-founded in 2021 by Dr. Haihua Yu, Dr. Yu Wang, and other biotech veterans, specializes in the development of novel targeted radiopharmaceuticals for cancer treatment. The company operates in the biopharmaceutical industry, focusing on visual diagnosis and treatment integrated nuclear drugs. Bivision's lead drug candidate, JH02, is a Lutetium-177 labeled small molecule ligand targeting Prostate Specific Membrane Antigen (PSMA) for treating metastatic castration-resistant prostate cancer (mCRPC). This drug has been approved by both the FDA and CDE and is currently in Phase I/II clinical trials. Bivision serves patients with advanced cancer, leveraging its proprietary technology platform to accelerate drug R&D programs to clinical stages more efficiently. The company generates revenue through the development and commercialization of its proprietary drugs, as well as potential partnerships and licensing agreements. Bivision's diversified R&D pipeline spans various stages of drug discovery and development, supported by a team with extensive experience in the pharmaceutical industry.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Jing'an District, China
- Open positions
- None listed
- Dealroom signal
- 22.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Health Diagnostics, Biotech and Pharma, Hard Tech, Radiopharmaceuticals, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | May 2026 | $55M | $220M | Ruihua Holdings · Wuxi Innovation Investment Group · Zhangjiang Hi-Tech Park · Shanghai Pudong Venture Capital | ↗ |
| SERIES BOther financing | Jan 2025 | $14M | $55M | CICC · Gaorong Capital · Trinity Innovation Fund | ↗ |
Growth signals
Latest recorded traffic for Bivision is 360 monthly website visits, up 80% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Yijing Capital- KCKaitai Capital
Virtus Inspire Ventures
Series A13 investors entered at this stage
- HIHuajin Investment
- HAHuajin Avenue
Gaorong Capital
Hangzhou Tigermed- LILichen Investment
CICC
Trinity Innovation Fund- ZPZhangjiang Hi-Tech Park
- SCShanghai Pudong Venture Capital
IDG Capital- RHRuihua Holdings
Wuxi Innovation Investment Group- GCGuohai Innovation Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bivision on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bivision’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.